pharmaceuticals

pharmaceuticals Articles

Syros Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
The annual meeting for ASCO is generally one of the biggest weeks of the year for the health care sector. However, there are inevitably winners and losers.
A few biotech companies made fantastic runs in Thursday’s session. We have included information about each company, as well as recent trading activity and the consensus price target.
A new study from IMS Health has projected that the global market for cancer treatments rose to $107 billion in 2015.
Merrill Lynch is one of the major firms that will be in attendance at the American Society of Clinical Oncology (ASCO) annual meeting, and it has issued a report on what it is looking for.
The American Society of Clinical Oncology (ASCO) is gearing up for its annual meeting. At this meeting, cancer drug developers will share the results from their most recent drug trials.
Here are seven speculative biotech and biohealth players in which analyst calls during the week ending May 27 have given major upside projections.
Shares of Titan Pharmaceuticals saw a handy gain early in Friday’s session following the U.S. Food and Drug Administration (FDA) approval of its partner’s opioid dependence treatment.
These two biotech companies not only have data that could prove to be huge, but the stocks have been absolutely hammered over the past year, offering the best entry points in some time.
Minerva Neurosciences saw its shares make absolutely massive gains on Thursday following the release of positive results from a couple mid-stage clinical trials.
Ionis Pharmaceuticals shares dropped severely after a less-than positive update on its IONIS-TTR Rx program.
Many companies are being discussed as Zika virus winners, but the reality is that many of them are so small or have sketchy histories. This is why we are featuring seven notable companies targeting...
Selecta Biosciences has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Despite the ongoing political candidate chirping, all of these quality big pharmaceutical stocks have been around, and they will continue to stay around.
24/7 Wall St. has collected several big FDA decisions and imminent clinical trial results that should be coming up in the June quarter. We have added some color.